323 related articles for article (PubMed ID: 36543113)
21. Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis.
Hao J; Yu H; Zhang T; An R; Xue Y
Ther Adv Med Oncol; 2020; 12():1758835920967241. PubMed ID: 33193829
[TBL] [Abstract][Full Text] [Related]
22. Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis.
Ozmadenci D; Shankara Narayanan JS; Andrew J; Ojalill M; Barrie AM; Jiang S; Iyer S; Chen XL; Rose M; Estrada V; Molinolo A; Bertotto T; Mikulski Z; McHale MC; White RR; Connolly DC; Pachter JA; Kuchroo VK; Stupack DG; Schlaepfer DD
Proc Natl Acad Sci U S A; 2022 Apr; 119(17):e2117065119. PubMed ID: 35467979
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of the immune microenvironment in ovarian cancer patients.
Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D
Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640
[TBL] [Abstract][Full Text] [Related]
24. Tumor infiltrating lymphocytes in ovarian cancer.
Santoiemma PP; Powell DJ
Cancer Biol Ther; 2015; 16(6):807-20. PubMed ID: 25894333
[TBL] [Abstract][Full Text] [Related]
25. Machine Learning Quantification of Intraepithelial Tumor-Infiltrating Lymphocytes as a Significant Prognostic Factor in High-Grade Serous Ovarian Carcinomas.
Machuca-Aguado J; Conde-Martín AF; Alvarez-Muñoz A; Rodríguez-Zarco E; Polo-Velasco A; Rueda-Ramos A; Rendón-García R; Ríos-Martin JJ; Idoate MA
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003250
[TBL] [Abstract][Full Text] [Related]
26. Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.
Sun J; Yan C; Xu D; Zhang Z; Li K; Li X; Zhou M; Hao D
Br J Cancer; 2022 Jun; 126(11):1570-1580. PubMed ID: 35017656
[TBL] [Abstract][Full Text] [Related]
27. Altered tumor signature and T-cell profile after chemotherapy reveal new therapeutic opportunities in high-grade serous ovarian carcinoma.
Kang H; Hwang S; Kang H; Jo A; Lee JM; Choi JK; An HJ; Lee HO
Cancer Sci; 2024 Mar; 115(3):989-1000. PubMed ID: 38226451
[TBL] [Abstract][Full Text] [Related]
28. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.
Geistlinger L; Oh S; Ramos M; Schiffer L; LaRue RS; Henzler CM; Munro SA; Daughters C; Nelson AC; Winterhoff BJ; Chang Z; Talukdar S; Shetty M; Mullany SA; Morgan M; Parmigiani G; Birrer MJ; Qin LX; Riester M; Starr TK; Waldron L
Cancer Res; 2020 Oct; 80(20):4335-4345. PubMed ID: 32747365
[TBL] [Abstract][Full Text] [Related]
29. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
30. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
31. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract][Full Text] [Related]
32. Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.
Tsuji T; Eng KH; Matsuzaki J; Battaglia S; Szender JB; Miliotto A; Gnjatic S; Bshara W; Morrison CD; Lele S; Emerson RO; Wang J; Liu S; Robins H; Lugade AA; Odunsi K
Oncotarget; 2020 Jul; 11(27):2669-2683. PubMed ID: 32676168
[TBL] [Abstract][Full Text] [Related]
33. Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints.
Hudry D; Le Guellec S; Meignan S; Bécourt S; Pasquesoone C; El Hajj H; Martínez-Gómez C; Leblanc É; Narducci F; Ladoire S
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358750
[TBL] [Abstract][Full Text] [Related]
34. TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones.
Kongkaew T; Thaiwong R; Tudsamran S; Sae-Jung T; Sengprasert P; Vasuratna A; Suppipat K; Reantragoon R
J Immunol Methods; 2022 Apr; 503():113229. PubMed ID: 35101548
[TBL] [Abstract][Full Text] [Related]
35. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
[TBL] [Abstract][Full Text] [Related]
36. Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma.
Peres LC; Colin-Leitzinger C; Sinha S; Marks JR; Conejo-Garcia JR; Alberg AJ; Bandera EV; Berchuck A; Bondy ML; Christensen BC; Cote ML; Doherty JA; Moorman PG; Peters ES; Moran Segura C; Nguyen JV; Schwartz AG; Terry PD; Wilson CM; Fridley BL; Schildkraut JM
Cancer Epidemiol Biomarkers Prev; 2022 May; 31(5):1006-1016. PubMed ID: 35244678
[TBL] [Abstract][Full Text] [Related]
37. Deciphering the transcriptomic landscape of tumor-infiltrating CD8 lymphocytes in B16 melanoma tumors with single-cell RNA-Seq.
Carmona SJ; Siddiqui I; Bilous M; Held W; Gfeller D
Oncoimmunology; 2020; 9(1):1737369. PubMed ID: 32313720
[TBL] [Abstract][Full Text] [Related]
38. Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response.
Cao K; Zhang G; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Oncoimmunology; 2021; 10(1):1969075. PubMed ID: 34527431
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
40. High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer.
Emerson RO; Sherwood AM; Rieder MJ; Guenthoer J; Williamson DW; Carlson CS; Drescher CW; Tewari M; Bielas JH; Robins HS
J Pathol; 2013 Dec; 231(4):433-440. PubMed ID: 24027095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
